ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishLi Auto
25 Feb 2024 05:05

HK Connect SOUTHBOUND Flows (To 23 Feb 2024); Selling of Consumer Stocks, But Big Buys of SOEs

SOUTHBOUND saw significant net buying in the first week after Chinese New Year. Large caps and SOEs were heavily bought. Especially in energy and...

Logo
398 Views
Share
23 Feb 2024 10:54

Hong Kong Buybacks Weekly (Feb 23rd): AIA, HSBC, Yum China

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK), HSBC...

Logo
409 Views
Share
20 Feb 2024 06:40

FXI Rebalance Preview: Three Potential Changes as Big Moves Unfold

There could be 3 changes for the FXI in March. Two changes were forecast much earlier while one is a very recent change. Short interest on Yankuang...

Logo
359 Views
Share
14 Feb 2024 08:00

Hong Kong Connect Flows (Feb 9th): Tencent

We have analyzed southbound Hong Kong connect flows in the past week and highlighted Hong Kong connect flows for Tencent.

Logo
1.3k Views
Share
14 Feb 2024 08:00

HK Short Interest Weekly: Hscei Etf, Bud Apac, CMB, Tencent, Wuxi Apptec, Wuxi Bio

We analyzed the latest HK SFC report for aggregate short position as of Feb 2nd and highlight short interest changes in Hscei Etf, Bud Apac, CMB,...

Logo
345 Views
Share
x